Biofrontera Inc. Increase Decrease In Operating Lease Liability
Biofrontera Inc. (BFRI) reported Increase Decrease In Operating Lease Liability of -$184.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-13
- Biofrontera Inc. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$174.00K.
- Biofrontera Inc. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$10.00K.
- Biofrontera Inc. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$137.00K.
- Biofrontera Inc. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$175.00K.
- Biofrontera Inc. increase decrease in operating lease liability for fiscal 2025 was -$683.00K.
- Biofrontera Inc. increase decrease in operating lease liability for fiscal 2024 was -$689.00K.
- Biofrontera Inc. increase decrease in operating lease liability for fiscal 2023 was -$657.00K.
- Biofrontera Inc. increase decrease in operating lease liability for fiscal 2022 was -$781.00K.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$174.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$184.00K 10-Q · filed 2026-08-13 | -$321.00K derived: sum of 3 quarters · filed 2026-08-13 | -$496.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$10.00K 10-Q · filed 2026-05-14 | -$147.00K derived: sum of 2 quarters · filed 2026-05-14 | -$322.00K derived: sum of 3 quarters · filed 2026-05-14 | -$514.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$137.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$312.00K derived: sum of 2 quarters · filed 2026-03-19 | -$504.00K derived: sum of 3 quarters · filed 2026-08-13 | -$683.00K 10-K · filed 2026-03-19 |
| 2025-09-30 | -$175.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$367.00K derived: sum of 2 quarters · filed 2026-08-13 | -$546.00K 10-Q · filed 2025-11-12 | -$724.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$192.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$371.00K 10-Q · filed 2026-08-13 | -$549.00K derived: sum of 3 quarters · filed 2026-08-13 | -$726.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$179.00K 10-Q · filed 2026-05-14 | -$357.00K derived: sum of 2 quarters · filed 2026-05-14 | -$534.00K derived: sum of 3 quarters · filed 2026-05-14 | -$702.00K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | -$178.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$355.00K derived: sum of 2 quarters · filed 2026-03-19 | -$523.00K derived: sum of 3 quarters · filed 2026-03-19 | -$689.00K 10-K · filed 2026-03-19 |
| 2024-09-30 | -$177.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$345.00K derived: sum of 2 quarters · filed 2025-11-12 | -$511.00K 10-Q · filed 2025-11-12 | -$793.00K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$168.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$334.00K 10-Q · filed 2025-08-13 | -$616.00K derived: sum of 3 quarters · filed 2025-08-13 | -$736.00K derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | -$166.00K 10-Q · filed 2025-05-15 | -$448.00K derived: sum of 2 quarters · filed 2025-05-15 | -$568.00K derived: sum of 3 quarters · filed 2025-05-15 | -$689.00K derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | -$282.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | -$402.00K derived: sum of 2 quarters · filed 2025-03-20 | -$523.00K derived: sum of 3 quarters · filed 2025-03-20 | -$657.00K 10-K · filed 2025-03-20 |
| 2023-09-30 | -$120.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$241.00K derived: sum of 2 quarters · filed 2024-11-14 | -$375.00K 10-Q · filed 2024-11-14 | |
| 2023-06-30 | -$121.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$255.00K 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | -$134.00K 10-Q · filed 2024-05-15 | |||
| 2022-12-31 | -$781.00K 10-K · filed 2024-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B |